Cancer Imaging In Clear Cell Renal Carcinoma Gets ODAC Attention As Pipeline Fills
This article was originally published in The Pink Sheet Daily
FDA’s Oncologic Drugs Advisory Committee will examine the extent (if any) to which the pre-surgical identification of clear cell carcinoma of the kidney using an imaging test provides useful clinical information. ASCO abstracts show considerable research interest in the area.
You may also be interested in...
Second-generation VEGF inhibitor Inlyta (axitinib) gained approval based as much on its complementary safety profile as its superiority in a head-to-head comparison with Bayer/Onyx’s Nexavar .
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.